OnCo
peoplePerson

Michael J. Morris

Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.

Medical oncologist who led VISION (177Lu-PSMA-617) and co-led PSMAfore and PSMA PET studies, and chaired the Alliance GU committee. Focus on radioligand therapy and imaging biomarkers in prostate cancer.

Role
Prostate Cancer Section Head, Genitourinary Oncology Service
Specialisms
Prostate cancerRadiopharmaceuticalsPSMA theranostics

Papers

2top
TitleJournalYear
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancerNew England Journal of Medicine2021
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)Lancet2024

Key papers

1top
rctNew England Journal of Medicine 2021changed practice
VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer

Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).

Connected

9top

cancers

1
Prostate cancer

technologies

2
PSMA PETRadioligand therapy (beta emitters)

targets

1
PSMA

drugs

1
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto

institutions

1
Memorial Sloan Kettering Cancer Center

trials

2
PSMAforeVISION

key papers

1
VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer